Tag: investigational new drug contract development and manufacturing organization (cdmo) market forecast

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Expansion Outlook: What Revenue Opportunities Are Ahead?

The investigational new drug contract development and manufacturing organization (cdmo) market has experienced strong expansion in recent years. It is anticipated to grow from $5.91 billion in 2025 to $6.33 billion in 2026, at a compound annual growth rate (CAGR) of 7.1%. The growth observed in the past can be attributed to factors such as the limited availability of CDMOs for investigational drugs, an increasing demand for small molecule synthesis, a reliance on conventional manufacturing services, growing clinical trial volumes, and the early adoption of regulatory support services.

The investigational new drug contract development and manufacturing organization (cdmo) market size is anticipated to experience substantial expansion in the upcoming years. Its valuation is projected to reach $8.17 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.6%. This growth during the forecast period can be attributed to the broadening of gene and cell therapy manufacturing capabilities, a heightened demand for monoclonal antibodies and recombinant proteins, increased investment in advanced formulation technologies, the implementation of scalable manufacturing platforms, and a rise in global biotechnology research collaborations. Significant trends expected in this period include an escalating demand for early-stage drug development services, the expansion of clinical trial material supply services, a stronger emphasis on regulatory compliance and quality standards, the development of biologics and advanced therapies, and the adoption of custom manufacturing solutions for both small and large molecules.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=65848155&type=smp&name=Investigational%20New%20Drug%20Contract%20Development%20And%20Manufacturing%20Organization%20%28CDMO%29%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Growth Factors Behind Sustained Expansion

The expansion of clinical trials is projected to fuel the advancement of the investigational new drug contract development and manufacturing organization (CDMO) market in the coming period. These trials are meticulously structured research endeavors that involve human volunteers to assess the safety and efficacy of medical treatments, procedures, or interventions within controlled environments. This increase in clinical trials primarily stems from the escalating need for novel therapies, with the rising prevalence of chronic and intricate diseases compelling pharmaceutical and biotechnology firms to create and evaluate new remedies. Investigational new drug CDMOs facilitate clinical trials by optimizing the production and formulation of drugs ready for testing, thereby guaranteeing a prompt and compliant provision of investigational products for every stage of a study. As an illustration, in December 2024, data from the Association of the British Pharmaceutical Industry, a UK-based pharmaceutical trade body, indicated that the overall number of industry-backed clinical trials commenced in the United Kingdom rose from 411 in 2022 to 426 in 2023. Concurrently, Phase III trial starts saw an increase of 16.5 percent during this identical timeframe, moving from 182 to 212. Consequently, the expanding volume of clinical trials is stimulating the development of the investigational new drug contract development and manufacturing organization (CDMO) market.

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Segment Analysis: What Are The Core Market Categories?

The investigational new drug contract development and manufacturing organization (cdmo) market covered in this report is segmented –

1) By Product: Small Molecules, Large Molecules

2) By Formulation Type: Solid Formulations, Liquid Formulations, Injectable Formulations

3) By Service Type: Clinical Trial Material Supply, Regulatory Support Services, Manufacturing Services

4) By End-User: Biotechnology Companies, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Small Molecules: Synthetic Small Molecules, Semi-synthetic Small Molecules, Peptide-based Small Molecules, Oligonucleotides

2) By Large Molecules: Monoclonal Antibodies (mAbs), Recombinant Proteins, Vaccines, Cell Therapy Products, Gene Therapy Products, RNA-based Therapeutics

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Industry Trends Fueling Future Revenue Growth

Leading companies in the investigational new drug contract development and manufacturing organization (CDMO) market are concentrating on strategic alliances to bolster their development capabilities and accelerate entry into clinical trials. Such strategic partnerships denote formal arrangements between two or more entities that collaborate to achieve common objectives, utilizing each other’s strengths, resources, or specialized knowledge for mutual benefits while maintaining their distinct autonomy. For example, in August 2023, Sartorius AG, a Germany-based life science company, collaborated with Repligen Corporation, a US-based life sciences company, to unveil an integrated system combining the BIOSTAT STR and XCell ATF technologies for upstream process intensification. This joint effort seeks to optimize biopharmaceutical production by enhancing both efficiency and scalability. The undertaking underscores Sartorius’ ongoing innovation in bioprocessing solutions, reaffirming its dedication to the advancement of the biomanufacturing industry.

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Top Companies Driving Competitive Growth

Major companies operating in the investigational new drug contract development and manufacturing organization (cdmo) market are Thermo Fisher Scientific Inc., Fresenius Kabi AG, Lonza Group Ltd., Catalent Inc., Samsung Biologics Co. Ltd., Fareva SA, Recipharm AB, PCI Pharma Services, Vetter Pharma, Delpharm, Kindeva Drug Delivery LP, Ajinomoto Bio-Pharma Services, Cenexi SAS, Grand River Aseptic Manufacturing Inc., INCOG BioPharma Services, Aurigene Pharmaceutical Services, Jubilant HollisterStier LLC, Symbiosis Pharmaceutical Services Ltd., Afton Scientific Corp., Amaran Biotech Inc.

View The Full Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Report:

https://thebusinessresearchcompany.com/report/investigational-new-drug-contract-development-and-manufacturing-organization-cdmo-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Regional Outlook: Where Is Opportunity Concentrated?

North America was the largest region in the investigational new drug contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the investigational new drug contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Expansion Outlook: What Revenue Opportunities Are Ahead?

The investigational new drug contract development and manufacturing organization (cdmo) market has experienced strong expansion in recent years. It is anticipated to grow from $5.91 billion in 2025 to $6.33 billion in 2026, at a compound annual growth rate (CAGR) of 7.1%. The growth observed in the past can be attributed to factors such as the limited availability of CDMOs for investigational drugs, an increasing demand for small molecule synthesis, a reliance on conventional manufacturing services, growing clinical trial volumes, and the early adoption of regulatory support services.

The investigational new drug contract development and manufacturing organization (cdmo) market size is anticipated to experience substantial expansion in the upcoming years. Its valuation is projected to reach $8.17 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.6%. This growth during the forecast period can be attributed to the broadening of gene and cell therapy manufacturing capabilities, a heightened demand for monoclonal antibodies and recombinant proteins, increased investment in advanced formulation technologies, the implementation of scalable manufacturing platforms, and a rise in global biotechnology research collaborations. Significant trends expected in this period include an escalating demand for early-stage drug development services, the expansion of clinical trial material supply services, a stronger emphasis on regulatory compliance and quality standards, the development of biologics and advanced therapies, and the adoption of custom manufacturing solutions for both small and large molecules.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=65848155&type=smp&name=Investigational%20New%20Drug%20Contract%20Development%20And%20Manufacturing%20Organization%20%28CDMO%29%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Growth Factors Behind Sustained Expansion

The expansion of clinical trials is projected to fuel the advancement of the investigational new drug contract development and manufacturing organization (CDMO) market in the coming period. These trials are meticulously structured research endeavors that involve human volunteers to assess the safety and efficacy of medical treatments, procedures, or interventions within controlled environments. This increase in clinical trials primarily stems from the escalating need for novel therapies, with the rising prevalence of chronic and intricate diseases compelling pharmaceutical and biotechnology firms to create and evaluate new remedies. Investigational new drug CDMOs facilitate clinical trials by optimizing the production and formulation of drugs ready for testing, thereby guaranteeing a prompt and compliant provision of investigational products for every stage of a study. As an illustration, in December 2024, data from the Association of the British Pharmaceutical Industry, a UK-based pharmaceutical trade body, indicated that the overall number of industry-backed clinical trials commenced in the United Kingdom rose from 411 in 2022 to 426 in 2023. Concurrently, Phase III trial starts saw an increase of 16.5 percent during this identical timeframe, moving from 182 to 212. Consequently, the expanding volume of clinical trials is stimulating the development of the investigational new drug contract development and manufacturing organization (CDMO) market.

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Segment Analysis: What Are The Core Market Categories?

The investigational new drug contract development and manufacturing organization (cdmo) market covered in this report is segmented –

1) By Product: Small Molecules, Large Molecules

2) By Formulation Type: Solid Formulations, Liquid Formulations, Injectable Formulations

3) By Service Type: Clinical Trial Material Supply, Regulatory Support Services, Manufacturing Services

4) By End-User: Biotechnology Companies, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Small Molecules: Synthetic Small Molecules, Semi-synthetic Small Molecules, Peptide-based Small Molecules, Oligonucleotides

2) By Large Molecules: Monoclonal Antibodies (mAbs), Recombinant Proteins, Vaccines, Cell Therapy Products, Gene Therapy Products, RNA-based Therapeutics

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Industry Trends Fueling Future Revenue Growth

Leading companies in the investigational new drug contract development and manufacturing organization (CDMO) market are concentrating on strategic alliances to bolster their development capabilities and accelerate entry into clinical trials. Such strategic partnerships denote formal arrangements between two or more entities that collaborate to achieve common objectives, utilizing each other’s strengths, resources, or specialized knowledge for mutual benefits while maintaining their distinct autonomy. For example, in August 2023, Sartorius AG, a Germany-based life science company, collaborated with Repligen Corporation, a US-based life sciences company, to unveil an integrated system combining the BIOSTAT STR and XCell ATF technologies for upstream process intensification. This joint effort seeks to optimize biopharmaceutical production by enhancing both efficiency and scalability. The undertaking underscores Sartorius’ ongoing innovation in bioprocessing solutions, reaffirming its dedication to the advancement of the biomanufacturing industry.

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Top Companies Driving Competitive Growth

Major companies operating in the investigational new drug contract development and manufacturing organization (cdmo) market are Thermo Fisher Scientific Inc., Fresenius Kabi AG, Lonza Group Ltd., Catalent Inc., Samsung Biologics Co. Ltd., Fareva SA, Recipharm AB, PCI Pharma Services, Vetter Pharma, Delpharm, Kindeva Drug Delivery LP, Ajinomoto Bio-Pharma Services, Cenexi SAS, Grand River Aseptic Manufacturing Inc., INCOG BioPharma Services, Aurigene Pharmaceutical Services, Jubilant HollisterStier LLC, Symbiosis Pharmaceutical Services Ltd., Afton Scientific Corp., Amaran Biotech Inc.

View The Full Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Report:

https://thebusinessresearchcompany.com/report/investigational-new-drug-contract-development-and-manufacturing-organization-cdmo-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Regional Outlook: Where Is Opportunity Concentrated?

North America was the largest region in the investigational new drug contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the investigational new drug contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Expansion Outlook: What Revenue Opportunities Are Ahead?

The investigational new drug contract development and manufacturing organization (cdmo) market has experienced strong expansion in recent years. It is anticipated to grow from $5.91 billion in 2025 to $6.33 billion in 2026, at a compound annual growth rate (CAGR) of 7.1%. The growth observed in the past can be attributed to factors such as the limited availability of CDMOs for investigational drugs, an increasing demand for small molecule synthesis, a reliance on conventional manufacturing services, growing clinical trial volumes, and the early adoption of regulatory support services.

The investigational new drug contract development and manufacturing organization (cdmo) market size is anticipated to experience substantial expansion in the upcoming years. Its valuation is projected to reach $8.17 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.6%. This growth during the forecast period can be attributed to the broadening of gene and cell therapy manufacturing capabilities, a heightened demand for monoclonal antibodies and recombinant proteins, increased investment in advanced formulation technologies, the implementation of scalable manufacturing platforms, and a rise in global biotechnology research collaborations. Significant trends expected in this period include an escalating demand for early-stage drug development services, the expansion of clinical trial material supply services, a stronger emphasis on regulatory compliance and quality standards, the development of biologics and advanced therapies, and the adoption of custom manufacturing solutions for both small and large molecules.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=65848155&type=smp&name=Investigational%20New%20Drug%20Contract%20Development%20And%20Manufacturing%20Organization%20%28CDMO%29%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Growth Factors Behind Sustained Expansion

The expansion of clinical trials is projected to fuel the advancement of the investigational new drug contract development and manufacturing organization (CDMO) market in the coming period. These trials are meticulously structured research endeavors that involve human volunteers to assess the safety and efficacy of medical treatments, procedures, or interventions within controlled environments. This increase in clinical trials primarily stems from the escalating need for novel therapies, with the rising prevalence of chronic and intricate diseases compelling pharmaceutical and biotechnology firms to create and evaluate new remedies. Investigational new drug CDMOs facilitate clinical trials by optimizing the production and formulation of drugs ready for testing, thereby guaranteeing a prompt and compliant provision of investigational products for every stage of a study. As an illustration, in December 2024, data from the Association of the British Pharmaceutical Industry, a UK-based pharmaceutical trade body, indicated that the overall number of industry-backed clinical trials commenced in the United Kingdom rose from 411 in 2022 to 426 in 2023. Concurrently, Phase III trial starts saw an increase of 16.5 percent during this identical timeframe, moving from 182 to 212. Consequently, the expanding volume of clinical trials is stimulating the development of the investigational new drug contract development and manufacturing organization (CDMO) market.

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Segment Analysis: What Are The Core Market Categories?

The investigational new drug contract development and manufacturing organization (cdmo) market covered in this report is segmented –

1) By Product: Small Molecules, Large Molecules

2) By Formulation Type: Solid Formulations, Liquid Formulations, Injectable Formulations

3) By Service Type: Clinical Trial Material Supply, Regulatory Support Services, Manufacturing Services

4) By End-User: Biotechnology Companies, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Small Molecules: Synthetic Small Molecules, Semi-synthetic Small Molecules, Peptide-based Small Molecules, Oligonucleotides

2) By Large Molecules: Monoclonal Antibodies (mAbs), Recombinant Proteins, Vaccines, Cell Therapy Products, Gene Therapy Products, RNA-based Therapeutics

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Industry Trends Fueling Future Revenue Growth

Leading companies in the investigational new drug contract development and manufacturing organization (CDMO) market are concentrating on strategic alliances to bolster their development capabilities and accelerate entry into clinical trials. Such strategic partnerships denote formal arrangements between two or more entities that collaborate to achieve common objectives, utilizing each other’s strengths, resources, or specialized knowledge for mutual benefits while maintaining their distinct autonomy. For example, in August 2023, Sartorius AG, a Germany-based life science company, collaborated with Repligen Corporation, a US-based life sciences company, to unveil an integrated system combining the BIOSTAT STR and XCell ATF technologies for upstream process intensification. This joint effort seeks to optimize biopharmaceutical production by enhancing both efficiency and scalability. The undertaking underscores Sartorius’ ongoing innovation in bioprocessing solutions, reaffirming its dedication to the advancement of the biomanufacturing industry.

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Top Companies Driving Competitive Growth

Major companies operating in the investigational new drug contract development and manufacturing organization (cdmo) market are Thermo Fisher Scientific Inc., Fresenius Kabi AG, Lonza Group Ltd., Catalent Inc., Samsung Biologics Co. Ltd., Fareva SA, Recipharm AB, PCI Pharma Services, Vetter Pharma, Delpharm, Kindeva Drug Delivery LP, Ajinomoto Bio-Pharma Services, Cenexi SAS, Grand River Aseptic Manufacturing Inc., INCOG BioPharma Services, Aurigene Pharmaceutical Services, Jubilant HollisterStier LLC, Symbiosis Pharmaceutical Services Ltd., Afton Scientific Corp., Amaran Biotech Inc.

View The Full Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Report:

https://thebusinessresearchcompany.com/report/investigational-new-drug-contract-development-and-manufacturing-organization-cdmo-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Regional Outlook: Where Is Opportunity Concentrated?

North America was the largest region in the investigational new drug contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the investigational new drug contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market CAGR Analysis And Future Market Development

Between 2025 and 2026, the investigational new drug contract development and manufacturing organization (CDMO) market is projected to expand from $5.91 billion to $6.33 billion, reflecting a compound annual growth rate (CAGR) of 7.1%. This strong growth in recent years has been driven by a scarcity of CDMOs specializing in investigational drugs, heightened demand for small molecule synthesis, continued dependence on traditional manufacturing services, rising numbers of clinical trials, and early uptake of regulatory support offerings.

The investigational new drug contract development and manufacturing organization (CDMO) market is projected to experience significant expansion over the coming years. By 2030, it is anticipated to reach a valuation of $8.17 billion, reflecting a compound annual growth rate (CAGR) of 6.6%. This forecasted growth is driven by several key factors, including the expansion of capabilities for gene and cell therapy manufacturing, heightened demand for monoclonal antibodies and recombinant proteins, investments in cutting-edge formulation technologies, the embrace of scalable manufacturing platforms, and strengthened global biotechnology research partnerships. Notable developments shaping this period include a surge in demand for services related to early-stage drug development, a rise in clinical trial material supply offerings, a growing emphasis on meeting regulatory and quality benchmarks, the broadening of biologics and advanced therapy development, and the adoption of bespoke manufacturing solutions for both small and large molecules.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25803&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Industry Drivers: What Is Driving Revenue Growth?

The projected expansion of the investigational new drug contract development and manufacturing organization (CDMO) market is expected to be driven by the increasing number of clinical trials. These trials are meticulously structured studies conducted with human volunteers to evaluate the safety and effectiveness of medical treatments, procedures, or interventions under regulated conditions. The growing need for novel therapies, spurred by rising rates of chronic and complex illnesses, is primarily fueling the surge in clinical trials, as pharmaceutical and biotech companies work to develop and test new therapeutic options. By optimizing the development and manufacturing of formulations ready for trials, investigational new drug CDMOs play a key role in supporting these studies, guaranteeing a timely and regulatory-compliant supply of investigational products for every stage of the research. For example, as reported in December 2024 by the Association of the British Pharmaceutical Industry, a trade association for the UK pharmaceutical sector, the total number of industry-initiated clinical trials in the United Kingdom grew from 411 in 2022 to 426 in 2023. Additionally, Phase III trial initiations saw a 16.5% increase over the same timeframe, moving from 182 to 212. Consequently, the growth of the investigational new drug contract development and manufacturing organization (CDMO) market is being propelled by the escalating volume of clinical trials.

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Segments: Where Are The Largest Growth Opportunities?

The investigational new drug contract development and manufacturing organization (cdmo) market covered in this report is segmented –

1) By Product: Small Molecules, Large Molecules

2) By Formulation Type: Solid Formulations, Liquid Formulations, Injectable Formulations

3) By Service Type: Clinical Trial Material Supply, Regulatory Support Services, Manufacturing Services

4) By End-User: Biotechnology Companies, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Small Molecules: Synthetic Small Molecules, Semi-synthetic Small Molecules, Peptide-based Small Molecules, Oligonucleotides

2) By Large Molecules: Monoclonal Antibodies (mAbs), Recombinant Proteins, Vaccines, Cell Therapy Products, Gene Therapy Products, RNA-based Therapeutics

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Growth Trends: What Is Influencing The Future Outlook?

Key industry players in the investigational new drug contract development and manufacturing organization (CDMO) market are actively forming strategic partnerships to improve their development capabilities and accelerate clinical-stage entry. These partnerships are defined as formal collaborations between two or more organizations that work together to achieve common goals by combining their strengths, resources, or expertise for mutual advantage while retaining their separate identities. To illustrate, in August 2023, Sartorius AG, a life science firm based in Germany, formed an alliance with Repligen Corporation, a US-based life sciences company, to introduce a combined system that integrates BIOSTAT STR and XCell ATF technologies for upstream process intensification. The purpose of this partnership is to streamline biopharmaceutical production through improved efficiency and scalability. This effort represents a step forward in Sartorius’ ongoing innovation with bioprocessing solutions, underscoring its dedication to advancing the biomanufacturing sector.

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Major Participants And Competitive Dynamics

Major companies operating in the investigational new drug contract development and manufacturing organization (cdmo) market are Thermo Fisher Scientific Inc., Fresenius Kabi AG, Lonza Group Ltd., Catalent Inc., Samsung Biologics Co. Ltd., Fareva SA, Recipharm AB, PCI Pharma Services, Vetter Pharma, Delpharm, Kindeva Drug Delivery LP, Ajinomoto Bio-Pharma Services, Cenexi SAS, Grand River Aseptic Manufacturing Inc., INCOG BioPharma Services, Aurigene Pharmaceutical Services, Jubilant HollisterStier LLC, Symbiosis Pharmaceutical Services Ltd., Afton Scientific Corp., Amaran Biotech Inc.

Access The Complete Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Report:

https://www.thebusinessresearchcompany.com/report/investigational-new-drug-contract-development-and-manufacturing-organization-cdmo-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Regional Analysis: Which Region Leads By Revenue?

North America was the largest region in the investigational new drug contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the investigational new drug contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Growth In Market Value Is Anticipated For The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Between 2026 And 2030?

The investigational new drug contract development and manufacturing organization (cdmo) market size has demonstrated significant expansion in recent years. It is forecast to increase from $5.91 billion in 2025 to $6.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.1%. The growth observed in the historic period can be linked to the limited availability of CDMOs for investigational drugs, an increasing demand for small molecule synthesis, reliance on conventional manufacturing services, rising clinical trial volumes, and the early adoption of regulatory support services.

The investigational new drug contract development and manufacturing organization (CDMO) market is poised for substantial growth in the upcoming years. It is anticipated to expand to $8.17 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.6%. This expansion during the forecast period is attributed to factors such as the broadening of gene and cell therapy manufacturing capabilities, a heightened demand for monoclonal antibodies and recombinant proteins, increased investment in advanced formulation technologies, the widespread adoption of scalable manufacturing platforms, and a rise in global biotechnology research collaborations. Key trends expected in the same period include a surging demand for early-stage drug development services, an increase in clinical trial material supply services, a stronger emphasis on regulatory compliance and quality standards, the ongoing development and expansion of biologics and advanced therapies, and the uptake of custom manufacturing solutions for both small and large molecules.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25803&type=smp

Which Drivers Are Advancing The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Growth?

The increasing number of clinical trials is projected to fuel the expansion of the investigational new drug contract development and manufacturing organization (CDMO) market moving forward. These trials are meticulously designed studies involving human subjects, conducted to evaluate the safety and effectiveness of a medical treatment, procedure, or intervention under controlled settings. The escalation in clinical trials is primarily driven by an increasing demand for innovative treatments, as the growing prevalence of chronic and complex diseases prompts pharmaceutical and biotech companies to develop and test new therapies. Investigational new drug CDMOs facilitate clinical trials by streamlining the development and manufacturing of drug formulations ready for trials, thus ensuring a timely and compliant provision of investigational products for each stage of the study. For instance, in December 2024, data from the Association of the British Pharmaceutical Industry, a UK-based pharmaceutical industry trade association, indicated that the total count of industry-sponsored clinical trials launched in the United Kingdom climbed from 411 in 2022 to 426 in 2023, while Phase III trial initiations saw a growth of 16.5 percent over the same period, increasing from 182 to 212. Therefore, the proliferation of clinical trials is propelling the growth of the investigational new drug contract development and manufacturing organization (CDMO) market.

How Does Segment Analysis Break Down The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Structure?

The investigational new drug contract development and manufacturing organization (cdmo) market covered in this report is segmented –

1) By Product: Small Molecules, Large Molecules

2) By Formulation Type: Solid Formulations, Liquid Formulations, Injectable Formulations

3) By Service Type: Clinical Trial Material Supply, Regulatory Support Services, Manufacturing Services

4) By End-User: Biotechnology Companies, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Small Molecules: Synthetic Small Molecules, Semi-synthetic Small Molecules, Peptide-based Small Molecules, Oligonucleotides

2) By Large Molecules: Monoclonal Antibodies (mAbs), Recombinant Proteins, Vaccines, Cell Therapy Products, Gene Therapy Products, RNA-based Therapeutics

What Trends Are Influencing The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Outlook?

Companies operating within the investigational new drug contract development and manufacturing organization (CDMO) market are increasingly focusing on strategic collaborations to bolster their development capabilities and accelerate their journey into clinical stages. These strategic partnerships involve formal alliances between two or more organizations that work together to achieve common objectives, leveraging each other’s strengths, resources, or specialized knowledge to secure mutual benefits while still operating as independent entities. For example, in August 2023, Sartorius AG, a German life science company, teamed up with Repligen Corporation, a US-based life sciences company, to launch an integrated system that combines BIOSTAT STR and XCell ATF technologies for upstream process intensification. This joint effort aims to optimize biopharmaceutical production by improving efficiency and scalability. The initiative demonstrates Sartorius’ ongoing commitment to innovation in bioprocessing solutions, further solidifying its dedication to advancing the biomanufacturing industry.

Which Key Players Are Active In The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market?

Major companies operating in the investigational new drug contract development and manufacturing organization (cdmo) market are Thermo Fisher Scientific Inc., Fresenius Kabi AG, Lonza Group Ltd., Catalent Inc., Samsung Biologics Co. Ltd., Fareva SA, Recipharm AB, PCI Pharma Services, Vetter Pharma, Delpharm, Kindeva Drug Delivery LP, Ajinomoto Bio-Pharma Services, Cenexi SAS, Grand River Aseptic Manufacturing Inc., INCOG BioPharma Services, Aurigene Pharmaceutical Services, Jubilant HollisterStier LLC, Symbiosis Pharmaceutical Services Ltd., Afton Scientific Corp., Amaran Biotech Inc.

Access The Complete Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Report:

https://www.thebusinessresearchcompany.com/report/investigational-new-drug-contract-development-and-manufacturing-organization-cdmo-global-market-report

Which Region Holds The Largest Share In The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market?

North America was the largest region in the investigational new drug contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the investigational new drug contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=25803&type=smp

Browse Through More Reports Similar to the Global Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market 2026, By The Business Research Company

Pharmaceutical Contract Developments And Manufacturing Organization Cmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-contract-developments-and-manufacturing-organization-cmo-global-market-report

Topical Drugs Contract Development And Manufacturing Organization Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/topical-drugs-contract-development-and-manufacturing-organization-cdmo-global-market-report

Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/advanced-therapy-medicinal-products-contract-development-and-manufacturing-organization-cdmo-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Market Size Trajectory Of The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market From 2026 To 2030?

The investigational new drug contract development and manufacturing organization (cdmo) market has shown strong expansion in recent years. It is anticipated to increase from $5.91 billion in 2025 to $6.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.1%. The growth observed in the past can be ascribed to factors like the limited availability of CDMOs for investigational drugs, an increasing demand for small molecule synthesis, a reliance on conventional manufacturing services, rising clinical trial volumes, and the early adoption of regulatory support services.

The investigational new drug contract development and manufacturing organization (cdmo) market is projected to experience robust expansion over the coming years. This market is forecast to reach $8.17 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.6%. Factors contributing to this anticipated growth include the broadening of gene and cell therapy manufacturing capacities, an increasing need for monoclonal antibodies and recombinant proteins, significant investments in cutting-edge formulation technologies, the implementation of scalable manufacturing platforms, and an uptick in worldwide biotechnology research partnerships. Key trends foreseen during this period encompass a heightened demand for drug development services in their early stages, an expansion of services related to the supply of clinical trial materials, a strengthened emphasis on adherence to regulatory standards and quality benchmarks, the broadening scope of biologics and advanced therapy development, and the integration of tailored manufacturing solutions for both small and large molecules.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25803&type=smp

Which Key Factors Are Driving The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Growth?

The anticipated increase in clinical trials is set to fuel the expansion of the investigational new drug contract development and manufacturing organization (CDMO) market in the future. These trials are meticulously structured studies involving human participants to evaluate the safety and effectiveness of a medical treatment, procedure, or intervention under controlled settings. The primary impetus behind the rise in clinical trials is the escalating demand for innovative treatments, as the growing incidence of chronic and complex diseases prompts pharmaceutical and biotechnology companies to develop and test new therapies. Investigational new drug CDMOs facilitate clinical trials by streamlining the development and manufacturing of trial-ready drug formulations, ensuring a timely and compliant supply of investigational products for each phase of the study. For instance, in December 2024, data from the Association of the British Pharmaceutical Industry, a UK-based pharmaceutical industry trade association, showed that the total number of industry-sponsored clinical trials initiated in the United Kingdom rose from 411 in 2022 to 426 in 2023. Additionally, Phase III trial initiations experienced a 16.5 percent growth over the same period, increasing from 182 to 212. Thus, the growing number of clinical trials is a key driver for the growth of the investigational new drug contract development and manufacturing organization (CDMO) market.

Which Segment Types Are Examined In The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Segment Study?

The investigational new drug contract development and manufacturing organization (cdmo) market covered in this report is segmented –

1) By Product: Small Molecules, Large Molecules

2) By Formulation Type: Solid Formulations, Liquid Formulations, Injectable Formulations

3) By Service Type: Clinical Trial Material Supply, Regulatory Support Services, Manufacturing Services

4) By End-User: Biotechnology Companies, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Small Molecules: Synthetic Small Molecules, Semi-synthetic Small Molecules, Peptide-based Small Molecules, Oligonucleotides

2) By Large Molecules: Monoclonal Antibodies (mAbs), Recombinant Proteins, Vaccines, Cell Therapy Products, Gene Therapy Products, RNA-based Therapeutics

What Trends Are Influencing The Evolution Of The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market?

Leading companies within the investigational new drug contract development and manufacturing organization (CDMO) market are emphasizing strategic alliances to bolster their development capabilities and expedite clinical entry. Strategic partnerships represent formal agreements between two or more organizations that cooperate to achieve shared objectives, leveraging each other’s strengths, resources, or expertise for mutual gains while remaining distinct entities. For instance, in August 2023, Sartorius AG, a life science company based in Germany, collaborated with Repligen Corporation, a US-based life sciences company, to launch an integrated system combining BIOSTAT STR and XCell ATF technologies for enhanced upstream process intensification. This joint effort aims to streamline biopharmaceutical production through improved efficiency and scalability. The initiative highlights Sartorius’ continuous innovation in bioprocessing solutions, affirming its dedication to advancing the biomanufacturing industry.

Which Players Are Part Of The Competitive Landscape Of The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market?

Major companies operating in the investigational new drug contract development and manufacturing organization (cdmo) market are Thermo Fisher Scientific Inc., Fresenius Kabi AG, Lonza Group Ltd., Catalent Inc., Samsung Biologics Co. Ltd., Fareva SA, Recipharm AB, PCI Pharma Services, Vetter Pharma, Delpharm, Kindeva Drug Delivery LP, Ajinomoto Bio-Pharma Services, Cenexi SAS, Grand River Aseptic Manufacturing Inc., INCOG BioPharma Services, Aurigene Pharmaceutical Services, Jubilant HollisterStier LLC, Symbiosis Pharmaceutical Services Ltd., Afton Scientific Corp., Amaran Biotech Inc.

Get The Full Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Report:

https://www.thebusinessresearchcompany.com/report/investigational-new-drug-contract-development-and-manufacturing-organization-cdmo-global-market-report

Where Is The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Most Concentrated Geographically?

North America was the largest region in the investigational new drug contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the investigational new drug contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/investigational-new-drug-contract-development-and-manufacturing-organization-cdmo-global-market-report

Browse Through More Reports Similar to the Global Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market 2026, By The Business Research Company

Pharmaceutical Contract Developments And Manufacturing Organization Cmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-contract-developments-and-manufacturing-organization-cmo-global-market-report

Topical Drugs Contract Development And Manufacturing Organization Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/topical-drugs-contract-development-and-manufacturing-organization-cdmo-global-market-report

Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/advanced-therapy-medicinal-products-contract-development-and-manufacturing-organization-cdmo-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Evolve From 2026 To 2030?

The investigational new drug contract development and manufacturing organization (cdmo) market size has demonstrated substantial growth in recent years. It is anticipated to expand from $5.91 billion in 2025 to $6.33 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.1%. This historical growth can be linked to factors such as the limited availability of CDMOs for investigational drugs, an increasing demand for small molecule synthesis, reliance on conventional manufacturing services, growing clinical trial volumes, and the early adoption of regulatory support services.

The investigational new drug contract development and manufacturing organization (cdmo) market is projected to experience robust expansion in the coming years, anticipated to reach $8.17 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.6%. This forecasted growth can be linked to several factors, including the increasing capacity for gene and cell therapy manufacturing, a surge in demand for monoclonal antibodies and recombinant proteins, significant investment in advanced formulation technologies, the implementation of scalable manufacturing platforms, and an increase in global biotechnology research partnerships. Key trends projected for this period encompass a heightened need for early-stage drug development support, an expansion in services related to clinical trial material supply, an intensified emphasis on adherence to regulatory and quality benchmarks, the broadening of biologics and advanced therapy development, and the uptake of bespoke manufacturing solutions for both small and large molecular compounds.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25803&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market?

The investigational new drug contract development and manufacturing organization (CDMO) market is projected to grow, driven by the increasing number of clinical trials. These trials are structured studies involving human participants, designed to assess the safety and efficacy of medical treatments, procedures, or interventions under controlled conditions. This rise in clinical trials is largely fueled by the escalating demand for innovative treatments, as the growing incidence of chronic and complex diseases pushes pharmaceutical and biotech companies to develop and test new therapies. Investigational new drug CDMOs contribute to clinical trials by streamlining the development and manufacturing of trial-ready drug formulations, ensuring a prompt and compliant supply of investigational products for each study phase. For instance, in December 2024, the Association of the British Pharmaceutical Industry, a UK-based pharmaceutical industry trade association, reported that the total number of industry-sponsored clinical trials initiated in the United Kingdom rose from 411 in 2022 to 426 in 2023. Additionally, Phase III trial initiations expanded by 16.5 percent during the same period, increasing from 182 to 212. Consequently, the rising volume of clinical trials is propelling the expansion of the investigational new drug contract development and manufacturing organization (CDMO) market.

Which Segment Areas Are Covered In The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Analysis?

The investigational new drug contract development and manufacturing organization (cdmo) market covered in this report is segmented –

1) By Product: Small Molecules, Large Molecules

2) By Formulation Type: Solid Formulations, Liquid Formulations, Injectable Formulations

3) By Service Type: Clinical Trial Material Supply, Regulatory Support Services, Manufacturing Services

4) By End-User: Biotechnology Companies, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Small Molecules: Synthetic Small Molecules, Semi-synthetic Small Molecules, Peptide-based Small Molecules, Oligonucleotides

2) By Large Molecules: Monoclonal Antibodies (mAbs), Recombinant Proteins, Vaccines, Cell Therapy Products, Gene Therapy Products, RNA-based Therapeutics

What Key Developments And Trends Are Impacting The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market?

Major companies operating in the investigational new drug contract development and manufacturing organization (CDMO) market are focusing on strategic partnerships to strengthen development capabilities and speed up clinical entry. Such partnerships involve formal alliances between two or more organizations that collaborate to achieve shared objectives, leveraging each other’s strengths, resources, or expertise to gain mutual benefits while remaining independent entities. For instance, in August 2023, Sartorius AG, a Germany-based life science company, partnered with Repligen Corporation, a US-based life sciences company, to launch an integrated system combining the BIOSTAT STR and XCell ATF technologies for upstream process intensification. This collaboration aims to streamline biopharmaceutical production by enhancing efficiency and scalability. The initiative marks Sartorius’ continued innovation in bioprocessing solutions, reinforcing its commitment to advancing the biomanufacturing industry.

Which Global Companies Are Actively Competing In The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market?

Major companies operating in the investigational new drug contract development and manufacturing organization (cdmo) market are Thermo Fisher Scientific Inc., Fresenius Kabi AG, Lonza Group Ltd., Catalent Inc., Samsung Biologics Co. Ltd., Fareva SA, Recipharm AB, PCI Pharma Services, Vetter Pharma, Delpharm, Kindeva Drug Delivery LP, Ajinomoto Bio-Pharma Services, Cenexi SAS, Grand River Aseptic Manufacturing Inc., INCOG BioPharma Services, Aurigene Pharmaceutical Services, Jubilant HollisterStier LLC, Symbiosis Pharmaceutical Services Ltd., Afton Scientific Corp., Amaran Biotech Inc.

Read the full investigational new drug contract development and manufacturing organization (cdmo) market report here:

https://www.thebusinessresearchcompany.com/report/investigational-new-drug-contract-development-and-manufacturing-organization-cdmo-global-market-report

What Are The Leading Geographic Regions In The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market?

North America was the largest region in the investigational new drug contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the investigational new drug contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25803&type=smp

Browse Through More Reports Similar to the Global Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market 2026, By The Business Research Company

Pharmaceutical Contract Developments And Manufacturing Organization Cmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-contract-developments-and-manufacturing-organization-cmo-global-market-report

Topical Drugs Contract Development And Manufacturing Organization Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/topical-drugs-contract-development-and-manufacturing-organization-cdmo-global-market-report

Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/advanced-therapy-medicinal-products-contract-development-and-manufacturing-organization-cdmo-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the investigational new drug contract development and manufacturing organization (cdmo) market from 2026–2035 with trusted insights from The Business Research Company

By how much is the Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market expected to grow between 2026 and 2030?

The investigational new drug contract development and manufacturing organization (cdmo) market size has shown substantial growth in recent years. It is forecast to increase from $5.91 billion in 2025 to $6.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.1%. The expansion observed in prior periods can be attributed to factors such as the restricted availability of CDMOs for investigational drugs, rising demand for small molecule synthesis, a reliance on conventional manufacturing services, escalating clinical trial volumes, and the early adoption of regulatory support services.

The investigational new drug contract development and manufacturing organization (cdmo) market size is projected to experience robust expansion over the coming years. This market is forecast to reach $8.17 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.6%. This anticipated growth during the forecast period stems from factors such as the broadening of gene and cell therapy manufacturing capacities, an increasing need for monoclonal antibodies and recombinant proteins, investments in sophisticated formulation technologies, the implementation of scalable manufacturing platforms, and an increase in worldwide biotechnology research partnerships. Key trends anticipated during this period encompass a heightened demand for drug development services in their early stages, an expansion in services related to the supply of clinical trial materials, a stronger emphasis on adhering to regulatory requirements and quality benchmarks, the proliferation of biologics and advanced therapy development, and the integration of customized manufacturing solutions for both small and large molecules.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25803&type=smp

Which Drivers Are Influencing Market Acceleration In The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market?

The escalating number of clinical trials is projected to fuel the expansion of the investigational new drug contract development and manufacturing organization (CDMO) market moving forward. Clinical trials themselves are meticulously planned studies with human participants, designed to evaluate the safety and effectiveness of medical treatments, procedures, or interventions under controlled conditions. This uptick in clinical trials is predominantly fueled by a heightened demand for innovative therapies, as the increasing burden of chronic and complex diseases prompts pharmaceutical and biotech companies to develop and evaluate new treatments. Investigational new drug CDMOs play a crucial role in supporting these trials by streamlining the development and manufacturing of trial-ready drug formulations, thereby ensuring a timely and compliant supply of investigational products for each stage of a study. For example, in December 2024, the Association of the British Pharmaceutical Industry, a UK-based pharmaceutical industry trade association, reported that the total number of industry-sponsored clinical trials initiated in the United Kingdom rose from 411 in 2022 to 426 in 2023. Concurrently, Phase III trial initiations saw a 16.5 percent increase over the same period, climbing from 182 to 212. Thus, the growing volume of clinical trials is undeniably a key driver for the investigational new drug contract development and manufacturing organization (CDMO) market’s growth.

What Segments Are Identified Within The Structure Of The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market?

The investigational new drug contract development and manufacturing organization (cdmo) market covered in this report is segmented –

1) By Product: Small Molecules, Large Molecules

2) By Formulation Type: Solid Formulations, Liquid Formulations, Injectable Formulations

3) By Service Type: Clinical Trial Material Supply, Regulatory Support Services, Manufacturing Services

4) By End-User: Biotechnology Companies, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Small Molecules: Synthetic Small Molecules, Semi-synthetic Small Molecules, Peptide-based Small Molecules, Oligonucleotides

2) By Large Molecules: Monoclonal Antibodies (mAbs), Recombinant Proteins, Vaccines, Cell Therapy Products, Gene Therapy Products, RNA-based Therapeutics

What Trends Are Expected To Impact The Competitive Landscape Of The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market?

Prominent companies within the investigational new drug contract development and manufacturing organization (CDMO) market are increasingly concentrating on forming strategic partnerships to bolster their development capacities and expedite clinical entry. Strategic partnerships are defined as formal collaborations between two or more entities that cooperate to achieve mutual objectives, leveraging each other’s strengths, resources, or expertise for shared benefits while maintaining their independent status. Illustratively, in August 2023, Sartorius AG, a Germany-based life science company, engaged in a partnership with Repligen Corporation, a US-based life sciences company, to introduce an integrated system that combines BIOSTAT STR and XCell ATF technologies for upstream process intensification. This collaboration is designed to streamline biopharmaceutical production by enhancing both efficiency and scalability. This initiative underscores Sartorius’ continuous innovation in bioprocessing solutions, reaffirming its commitment to advancing the biomanufacturing sector.

Which Major Firms Are Strengthening Their Position In The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market?

Major companies operating in the investigational new drug contract development and manufacturing organization (cdmo) market are Thermo Fisher Scientific Inc., Fresenius Kabi AG, Lonza Group Ltd., Catalent Inc., Samsung Biologics Co. Ltd., Fareva SA, Recipharm AB, PCI Pharma Services, Vetter Pharma, Delpharm, Kindeva Drug Delivery LP, Ajinomoto Bio-Pharma Services, Cenexi SAS, Grand River Aseptic Manufacturing Inc., INCOG BioPharma Services, Aurigene Pharmaceutical Services, Jubilant HollisterStier LLC, Symbiosis Pharmaceutical Services Ltd., Afton Scientific Corp., Amaran Biotech Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/investigational-new-drug-contract-development-and-manufacturing-organization-cdmo-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market?

North America was the largest region in the investigational new drug contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the investigational new drug contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25803&type=smp

Browse Through More Reports Similar to the Global Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market 2026, By The Business Research Company

Pharmaceutical Contract Developments And Manufacturing Organization Cmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-contract-developments-and-manufacturing-organization-cmo-global-market-report

Topical Drugs Contract Development And Manufacturing Organization Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/topical-drugs-contract-development-and-manufacturing-organization-cdmo-global-market-report

Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/advanced-therapy-medicinal-products-contract-development-and-manufacturing-organization-cdmo-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Expected To Become By 2029 Compared With Its 2025 Level?

The investigational new drug contract development and manufacturing organization (CDMO) market has experienced substantial growth in recent years. It is anticipated to expand from $5.53 billion in 2024 to $5.91 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.0%. This historical growth can be attributed to factors such as increasing demand for early-phase clinical trials, greater outsourcing by pharmaceutical companies, an increase in the development of biologics and complex molecules, growing regulatory support for accelerated drug approvals, and a heightened focus on cost-efficiency and speed-to-market.

The investigational new drug contract development and manufacturing organization (CDMO) market is projected to experience robust expansion over the coming years. This market is set to reach $7.67 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.7%. Key factors driving this growth during the forecast period include a heightened focus on the development of rare and orphan drugs, a greater demand for integrated preclinical-to-clinical services, the increasing intricacy of biologics and gene therapies, rising investment in small molecule innovation, and the growing adoption of virtual pharmaceutical business models. Significant trends anticipated in the forecast period involve progress in integrated drug development platforms, the emergence of AI-driven clinical trial designs, innovations in personalized medicine manufacturing, improvements in regulatory compliance technologies, and the establishment of flexible and modular manufacturing facilities.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25803&type=smp

Which Industry Drivers Are Expected To Accelerate The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market From 2025 To 2029?

The expansion of clinical trials is projected to fuel the growth of the investigational new drug contract development and manufacturing organization (CDMO) market in the coming years. These trials are meticulously structured research endeavors that involve human participants, designed to evaluate the safety and efficacy of medical interventions, treatments, or procedures within controlled settings. The uptick in clinical trials primarily stems from an increasing need for novel therapies, as the rising prevalence of chronic and intricate diseases encourages pharmaceutical and biotechnology firms to develop and assess new treatments. Investigational new drug CDMOs play a crucial role in supporting clinical trials by optimizing the development and production of drug formulations suitable for trials, thereby guaranteeing a prompt and compliant provision of investigational products for every stage of a study. For example, in November 2023, the Association of the British Pharmaceutical Industry, a UK-based trade body, reported that the UK experienced a 4.3% increase in the annual number of industry-led clinical trials, climbing from 394 in 2021 to 411 in 2022. Consequently, the increasing volume of clinical trials is a key factor propelling the expansion of the investigational new drug contract development and manufacturing organization (CDMO) market.

Which Key Segments Fueling The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market?

The investigational new drug contract development and manufacturing organization (cdmo) market covered in this report is segmented –

1) By Product: Small Molecules, Large Molecules

2) By Formulation Type: Solid Formulations, Liquid Formulations, Injectable Formulations

3) By Service Type: Clinical Trial Material Supply, Regulatory Support Services, Manufacturing Services

4) By End-User: Biotechnology Companies, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Small Molecules: Synthetic Small Molecules, Semi-synthetic Small Molecules, Peptide-based Small Molecules, Oligonucleotides

2) By Large Molecules: Monoclonal Antibodies (mAbs), Recombinant Proteins, Vaccines, Cell Therapy Products, Gene Therapy Products, RNA-based Therapeutics

Which Trends Are Impacting The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market?

Leading firms within the investigational new drug contract development and manufacturing organization (CDMO) market are prioritizing strategic alliances to enhance their development proficiencies and accelerate their progression into clinical stages. Such partnerships represent formal collaborations among multiple organizations, designed to pursue common goals by utilizing their collective strengths, assets, or specialized knowledge for reciprocal advantages, all while maintaining their individual autonomy. A notable illustration occurred in August 2023, when Sartorius AG, a life science company headquartered in Germany, collaborated with Repligen Corporation, a US-based life sciences firm, to introduce an integrated system that merges BIOSTAT STR and XCell ATF technologies for optimizing upstream processes. The objective of this joint effort is to streamline biopharmaceutical manufacturing through improvements in both efficiency and scalability. This endeavor underscores Sartorius’ ongoing commitment to innovation in bioprocessing solutions, further solidifying its dedication to progressing the biomanufacturing sector.

Which Key Players Are Driving Competition In The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market?

Major companies operating in the investigational new drug contract development and manufacturing organization (cdmo) market are Thermo Fisher Scientific Inc., Fresenius Kabi AG, Lonza Group Ltd., Catalent Inc., Samsung Biologics Co. Ltd., Fareva SA, Recipharm AB, PCI Pharma Services, Vetter Pharma, Delpharm, Kindeva Drug Delivery LP, Ajinomoto Bio-Pharma Services, Cenexi SAS, Grand River Aseptic Manufacturing Inc., INCOG BioPharma Services, Aurigene Pharmaceutical Services, Jubilant HollisterStier LLC, Symbiosis Pharmaceutical Services Ltd., Afton Scientific Corp., Amaran Biotech Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/investigational-new-drug-contract-development-and-manufacturing-organization-cdmo-global-market-report

What Are The Regional Market Dynamics Impacting The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Industry?

North America was the largest region in the investigational new drug contract development and manufacturing organization (CDMO) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the investigational new drug contract development and manufacturing organization (cdmo) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25803&type=smp

Browse Through More Reports Similar to the Global Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market 2025, By The Business Research Company

Pharmaceutical Contract Developments And Manufacturing Organization Cmo Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmaceutical-contract-developments-and-manufacturing-organization-cmo-global-market-report

Topical Drugs Contract Development And Manufacturing Organization Cdmo Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/topical-drugs-contract-development-and-manufacturing-organization-cdmo-global-market-report

Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization Cdmo Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/advanced-therapy-medicinal-products-contract-development-and-manufacturing-organization-cdmo-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model